Eton Pharmaceuticals (ETON) Stock Forecast, Price Target & Predictions
ETON Stock Forecast
Eton Pharmaceuticals stock forecast is as follows: an average price target of $13.00 (represents a 3.42% upside from ETON’s last price of $12.57) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
ETON Price Target
The average price target for Eton Pharmaceuticals (ETON) is $13.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $11.00. This represents a potential 3.42% upside from ETON's last price of $12.57.
ETON Analyst Ratings
According to 6 Wall Street analysts, Eton Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for ETON stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Eton Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | Chase Knickerbocker | Craig-Hallum | $15.00 | $8.44 | 77.73% | 19.33% |
| Oct 04, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $11.00 | $6.91 | 59.19% | -12.49% |
| May 06, 2024 | Chase Knickerbocker | Craig-Hallum | $8.00 | $3.71 | 115.63% | -36.36% |
| Jul 25, 2022 | H.C. Wainwright | $9.00 | $2.72 | 230.88% | -28.40% |
The latest Eton Pharmaceuticals stock forecast, released on Oct 28, 2024 by Chase Knickerbocker from Craig-Hallum, set a price target of $15.00, which represents a 77.73% increase from the stock price at the time of the forecast ($8.44), and a 19.33% increase from ETON last price ($12.57).
Eton Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $13.00 | $11.33 |
| Last Closing Price | $12.57 | $12.57 | $12.57 |
| Upside/Downside | -100.00% | 3.42% | -9.86% |
In the current month, the average price target of Eton Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Eton Pharmaceuticals's last price of $12.57. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 28, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Oct 04, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Oct 04, 2024 | Deutsche Bank | Buy | Buy | Hold |
| Oct 04, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Oct 04, 2024 | Macquarie | Buy | Buy | Hold |
| Oct 04, 2024 | Cowen & Co. | Buy | Upgrade | |
| Oct 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 06, 2024 | Craig-Hallum | Buy | Initialise |
Eton Pharmaceuticals's last stock rating was published by Craig-Hallum on Oct 28, 2024. The company gave ETON a "Buy" rating, the same as its previous rate.
Eton Pharmaceuticals Financial Forecast
Eton Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $7.03M | $12.00M | $5.30M | $8.50M | $3.22M | $7.36M | $2.18M | $6.09M | $775.00K | $3.07M | $11.90M | $81.00K | $-161.00K | $20.00K | $99.00K | $459.00K | - |
| Avg Forecast | $20.45M | $18.45M | $15.45M | $14.05M | $10.55M | $9.70M | $8.80M | $7.70M | $7.70M | $6.26M | $6.50M | $4.60M | $9.10M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $777.78K |
| High Forecast | $21.16M | $19.09M | $15.99M | $14.54M | $10.92M | $9.79M | $9.11M | $7.97M | $7.97M | $6.48M | $6.73M | $4.76M | $9.42M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $933.33K |
| Low Forecast | $19.74M | $17.81M | $14.91M | $13.56M | $10.18M | $9.60M | $8.49M | $7.43M | $7.43M | $6.04M | $6.27M | $4.44M | $8.78M | $3.05M | $7.80M | $7.10M | $7.56M | $3.04M | $3.83M | $12.05M | $1.04M | $1.06M | $294.33K | $1.51M | $670.33K | $622.22K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 1.85% | 1.15% | 0.93% | 1.06% | 0.94% | 0.31% | 0.81% | 0.25% | 0.80% | 0.99% | 0.08% | -0.15% | 0.07% | 0.07% | 0.68% | - |
Eton Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $7.70M, with a low forecast of $7.43M, and a high forecast of $7.97M. ETON's average Quarter revenue forecast represents a 9.56% increase compared to the company's last Quarter revenue of $7.03M (Sep 23).
Eton Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-548.00K | $3.88M | $-2.32M | $1.06M | $-2.73M | $-169.00K | $-4.91M | $1.45M | $-6.01M | $-1.93M | $5.52M | $-7.53M | $-6.34M | $-4.57M | $-8.89M | $-2.55M | $-3.13M |
| Avg Forecast | $-9.68M | $-8.73M | $-7.31M | $-6.65M | $-4.99M | $-4.59M | $-4.16M | $-3.64M | $-3.64M | $-2.96M | $-3.08M | $-2.18M | $-4.31M | $-1.44M | $-3.68M | $-3.07M | $-3.57M | $-1.44M | $-1.81M | $5.52M | $-492.18K | $-500.37K | $-139.03K | $-4.61M | $-316.63K | $-4.38M |
| High Forecast | $-9.34M | $-8.42M | $-7.05M | $-6.42M | $-4.82M | $-4.54M | $-4.02M | $-3.52M | $-3.52M | $-2.86M | $-2.97M | $-2.10M | $-4.16M | $-1.44M | $-3.68M | $-2.45M | $-3.57M | $-1.44M | $-1.81M | $6.62M | $-492.18K | $-500.37K | $-139.03K | $-3.69M | $-316.63K | $-3.50M |
| Low Forecast | $-10.01M | $-9.03M | $-7.57M | $-6.88M | $-5.17M | $-4.63M | $-4.31M | $-3.77M | $-3.77M | $-3.06M | $-3.18M | $-2.25M | $-4.46M | $-1.44M | $-3.68M | $-3.68M | $-3.57M | $-1.44M | $-1.81M | $4.41M | $-492.18K | $-500.37K | $-139.03K | $-5.53M | $-316.63K | $-5.25M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.19% | -1.26% | 1.07% | -0.25% | 1.89% | 0.05% | 1.60% | -0.41% | 4.18% | 1.07% | 1.00% | 15.29% | 12.67% | 32.84% | 1.93% | 8.05% | 0.71% |
1 analysts predict ETON's average Quarter EBITDA for Sep 23 to be $-2.96M, with a high of $-2.86M and a low of $-3.06M. This is -176.27% lower than Eton Pharmaceuticals's previous annual EBITDA (Jun 23) of $3.88M.
Eton Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $-579.00K | $4.56M | $-2.91M | $912.00K | $-3.19M | $-1.78M | $-5.57M | $764.00K | $-6.09M | $-2.02M | $5.12M | $-7.69M | $-6.50M | $-4.73M | $-9.05M | $-2.70M | $-3.25M |
| Avg Forecast | $4.78M | $3.58M | $1.59M | $1.19M | $-265.50K | $-265.50K | $-1.86M | $-1.86M | $-1.06M | $-2.65M | $-2.39M | $-3.72M | $265.50K | $-3.87M | $773.34K | $-3.33M | $1.29M | $-3.48M | $-3.61M | $5.12M | $-6.83M | $-6.53M | $-6.70M | $-4.69M | $-6.79M | $-4.41M |
| High Forecast | $5.00M | $3.75M | $1.67M | $1.25M | $-253.44K | $-253.44K | $-1.77M | $-1.77M | $-1.01M | $-2.53M | $-2.28M | $-3.55M | $277.56K | $-3.87M | $773.34K | $-2.67M | $1.29M | $-3.48M | $-3.61M | $6.14M | $-6.83M | $-6.53M | $-6.70M | $-3.75M | $-6.79M | $-3.53M |
| Low Forecast | $4.56M | $3.42M | $1.52M | $1.14M | $-277.56K | $-277.56K | $-1.94M | $-1.94M | $-1.11M | $-2.78M | $-2.50M | $-3.89M | $253.44K | $-3.87M | $773.34K | $-4.00M | $1.29M | $-3.48M | $-3.61M | $4.09M | $-6.83M | $-6.53M | $-6.70M | $-5.63M | $-6.79M | $-5.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -1.91% | 0.78% | 3.44% | 0.83% | -2.30% | 1.67% | 0.59% | 1.75% | 0.56% | 1.00% | 1.13% | 1.00% | 0.71% | 1.93% | 0.40% | 0.74% |
Eton Pharmaceuticals's average Quarter net income forecast for Sep 23 is $-2.65M, with a range of $-2.78M to $-2.53M. ETON's average Quarter net income forecast represents a -158.24% decrease compared to the company's last Quarter net income of $4.56M (Jun 23).
Eton Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $4.34M | $4.67M | $5.34M | $4.35M | $4.17M | $5.26M | $4.93M | $3.82M | $3.33M | $3.27M | $4.06M | $3.80M | $3.43M | $2.92M | $2.61M | $2.43M | $1.91M |
| Avg Forecast | $1.38B | $1.24B | $1.04B | $947.50M | $711.47M | $653.84M | $593.45M | $519.27M | $519.27M | $422.09M | $438.35M | $310.21M | $613.69M | $205.62M | $526.02M | $3.08M | $510.03M | $205.08M | $258.42M | $4.06M | $70.27M | $71.44M | $19.85M | $1.35M | $45.21M | $52.45M |
| High Forecast | $1.43B | $1.29B | $1.08B | $980.61M | $736.33M | $660.44M | $614.19M | $537.42M | $537.42M | $436.84M | $453.66M | $321.06M | $635.13M | $205.62M | $526.02M | $3.70M | $510.03M | $205.08M | $258.42M | $4.87M | $70.27M | $71.44M | $19.85M | $1.62M | $45.21M | $62.94M |
| Low Forecast | $1.33B | $1.20B | $1.01B | $914.39M | $686.61M | $647.25M | $572.72M | $501.13M | $501.13M | $407.34M | $423.03M | $299.37M | $592.24M | $205.62M | $526.02M | $2.46M | $510.03M | $205.08M | $258.42M | $3.25M | $70.27M | $71.44M | $19.85M | $1.08M | $45.21M | $41.96M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.01% | 0.01% | 0.02% | 0.01% | 0.02% | 0.01% | 1.60% | 0.01% | 0.02% | 0.01% | 1.00% | 0.05% | 0.05% | 0.15% | 1.93% | 0.05% | 0.04% |
Eton Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $519.27M, based on 1 Wall Street analysts, with a range of $501.13M to $537.42M. The forecast indicates a 11875.84% rise compared to ETON last annual SG&A of $4.34M (Sep 23).
Eton Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 7 | 9 | 9 | 9 | 9 | 13 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.02 | $0.18 | $-0.11 | $0.04 | $-0.13 | $-0.07 | $-0.22 | $0.03 | $-0.24 | $-0.08 | $0.21 | $-0.32 | $-0.31 | $-0.23 | $-0.50 | $-0.15 | $-0.18 |
| Avg Forecast | $0.18 | $0.14 | $0.06 | $0.04 | $-0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.14 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| High Forecast | $0.19 | $0.14 | $0.06 | $0.05 | $-0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.13 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Low Forecast | $0.17 | $0.13 | $0.06 | $0.04 | $-0.01 | $-0.01 | $-0.07 | $-0.07 | $-0.04 | $-0.10 | $-0.09 | $-0.15 | $0.01 | $-0.15 | $0.03 | $-0.08 | $0.05 | $-0.14 | $-0.14 | $0.19 | $-0.27 | $-0.25 | $-0.26 | $-0.22 | $-0.26 | $-0.28 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.22% | -2.00% | 0.79% | 4.00% | 0.87% | -2.36% | 2.75% | 0.60% | 1.78% | 0.57% | 1.11% | 1.21% | 1.22% | 0.88% | 2.24% | 0.57% | 0.65% |
According to 1 Wall Street analysts, Eton Pharmaceuticals's projected average Quarter EPS for Sep 23 is $-0.10, with a low estimate of $-0.10 and a high estimate of $-0.10. This represents a -155.56% decrease compared to ETON previous annual EPS of $0.18 (Jun 23).
Eton Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.67 | $6.00 | 795.52% | Buy |
| BDTX | Black Diamond Therapeutics | $2.50 | $20.00 | 700.00% | Buy |
| GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
| ALDX | Aldeyra Therapeutics | $5.33 | $12.00 | 125.14% | Buy |
| ALEC | Alector | $1.89 | $4.00 | 111.64% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| CNTB | Connect Biopharma | $1.06 | $1.50 | 41.51% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
| TARS | Tarsus Pharmaceuticals | $53.26 | $63.00 | 18.29% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| ETON | Eton Pharmaceuticals | $12.64 | $13.00 | 2.85% | Buy |